 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- | rilematovir (JNJ-53718678) / J&J
Journal: Discovery of potential RSV fusion protein inhibitors from benzimidazole derivatives using QSAR, molecular docking, and ADMET evaluation methods. (Pubmed Central) - Sep 25, 2025
Furthermore, we used the optimal toxicity model to assess their cytotoxicity, and identified 23 derivatives with predicted cytotoxicity lower than that of JNJ-53718678. Finally, through drug-likeness evaluation, ADMET analysis and molecular dynamics simulation, we obtained eight potential RSV inhibitors with higher inhibitory activity, lower cytotoxicity, and better pharmacokinetic properties compared to JNJ-53718678.
- rilematovir (JNJ-53718678) / J&J
Phase classification: A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease (clinicaltrials.gov) - Feb 4, 2025
P2, N=22, Completed, Sponsor: Janssen Research & Development, LLC
Finally, through drug-likeness evaluation, ADMET analysis and molecular dynamics simulation, we obtained eight potential RSV inhibitors with higher inhibitory activity, lower cytotoxicity, and better pharmacokinetic properties compared to JNJ-53718678. Phase classification: P2a --> P2
- rilematovir (JNJ-53718678) / J&J
Phase classification: PRIMROSE: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov) - Sep 24, 2024
P2, N=5, Terminated, Sponsor: Janssen Research & Development, LLC
Phase classification: P2a --> P2 Phase classification: P2b --> P2
- Patient-Derived Airway Organoids: a Pre-clinical Platform to Model RSV Infection (408 A) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_839;
- || PC786 / Pulmocide
Review, Journal: Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development. (Pubmed Central) - Sep 1, 2024
Moving forward, passive immunisation and treatment options for RSV infection will play a significant role in reducing the health burden of RSV, complementing recent advancements in vaccine development. TRIAL REGISTRATION: PROSPERO registration: CRD42022376633.
- | rilematovir (JNJ-53718678) / J&J
Phase classification: A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus (clinicaltrials.gov) - Aug 30, 2024
P2, N=72, Completed, Sponsor: Janssen Research & Development, LLC
TRIAL REGISTRATION: PROSPERO registration: CRD42022376633. Phase classification: P2a --> P2
- || rilematovir (JNJ-53718678) / J&J
Clinical data, P2 data, Journal: CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ? (Pubmed Central) - Apr 23, 2024
P2
Data from the combined cohort suggest that rilematovir has a small but favorable antiviral effect of indeterminate clinical relevance compared with placebo, as well as a favorable safety profile. Safe and effective therapeutic options for RSV in infants and young children remain an unmet need.
- || rilematovir (JNJ-53718678) / J&J
Clinical data, P2a data, Journal: A pilot phase 2a, randomised, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalised adults with respiratory syncytial virus (RSV) infection. (Pubmed Central) - Sep 26, 2023
P2a
Safe and effective therapeutic options for RSV in infants and young children remain an unmet need. Rilematovir use, initiated early, suggests a potential clinical benefit in RSV-infected adults, with data supporting development of RSV therapeutic options.
- rilematovir (JNJ-53718678) / J&J
Dose adjustment of rilematovir in combination with CYP3A4 inhibitors based on PBPK modeling and clinical data (POSTER BOARD NO. 198) - Oct 4, 2022 - Abstract #ISIRVRSV2022ISIRV_RSV_275;
- rilematovir (JNJ-53718678) / J&J
Enrollment change, Trial completion date, Trial termination: A Study of JNJ-53718678 in Participants With Hepatic Impairment (clinicaltrials.gov) - Jun 13, 2022
P1, N=25, Terminated, Sponsor: Janssen Research & Development, LLC
N=52 --> 25 | Trial completion date: Dec 2022 --> Mar 2022 | Recruiting --> Terminated; A strategic decision was made to discontinue the study. The decision was not based on a safety concern.
- |||||| rilematovir (JNJ-53718678) / J&J
Trial completion date, Trial termination, Trial primary completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - May 16, 2022
P2, N=246, Terminated, Sponsor: Janssen Research & Development, LLC
Trial completion date: Apr 2024 --> Apr 2022 | Recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Apr 2022; Janssen made the strategic decision to discontinue the CROCuS study. This decision is not based on any safety concerns.
- | rilematovir (JNJ-53718678) / J&J
Trial completion date: A Study of JNJ-53718678 in Participants With Hepatic Impairment (clinicaltrials.gov) - May 11, 2022
P1, N=52, Recruiting, Sponsor: Janssen Research & Development, LLC
This decision is not based on any safety concerns. Trial completion date: Apr 2022 --> Dec 2022
- | rilematovir (JNJ-53718678) / J&J
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PRIMROSE: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov) - Apr 28, 2022
P2b, N=6, Terminated, Sponsor: Janssen Research & Development, LLC
N=180 --> 6 | Trial completion date: Dec 2023 --> Mar 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Mar 2022; Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.
- | rilematovir (JNJ-53718678) / J&J
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: DAISY: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Apr 18, 2022
P3, N=28, Terminated, Sponsor: Janssen Research & Development, LLC
N=737 --> 28 | Trial completion date: May 2025 --> Mar 2022 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Mar 2022; Janssen made the strategic decision to discontinue the DAISY study. This decision is not based on any safety concerns.
- || rilematovir (JNJ-53718678) / J&J
Trial completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Apr 13, 2022
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
This decision is not based on any safety concerns. Trial completion date: Mar 2023 --> Apr 2024
- rilematovir (JNJ-53718678) / J&J
Trial completion date, Trial termination, Trial primary completion date: FREESIA: Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Mar 18, 2022
P2, N=3, Terminated, Sponsor: Janssen Sciences Ireland UC
Trial completion date: Aug 2025 --> Feb 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Dec 2021; A strategic decision was made to discontinue the study. The decision was not based on a safety concern.
- || rilematovir (JNJ-53718678) / J&J
Trial completion: A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir (clinicaltrials.gov) - Feb 17, 2022
P1, N=18, Completed, Sponsor: Janssen Research & Development, LLC
The decision was not based on a safety concern. Recruiting --> Completed
- | rilematovir (JNJ-53718678) / J&J
Journal: Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents. (Pubmed Central) - Dec 29, 2021
A deepen comparison of the related electrostatic features and H-bonding motifs allowed us to pave the way for the following molecular dynamic simulation of JNJ-53718678 and then to perform docking studies of the in-house library of potent benzimidazole-containing anti-RSV agents...Along with this, in silico prediction of absorption, distribution, metabolism, excretion (ADME) properties, and also of possible off-target events was performed. The results highlighted once more that the benzimidazole ring represents a privileged scaffold whose properties deserve to be further investigated for the rational design of novel and orally bioavailable anti-RSV agents.
- || rilematovir (JNJ-53718678) / J&J
New P1 trial: A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir (clinicaltrials.gov) - Dec 12, 2021
P1, N=18, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||| rilematovir (JNJ-53718678) / J&J
Enrollment closed, Enrollment change: FREESIA: Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Nov 24, 2021
P2, N=3, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
The results highlighted once more that the benzimidazole ring represents a privileged scaffold whose properties deserve to be further investigated for the rational design of novel and orally bioavailable anti-RSV agents. Recruiting --> Active, not recruiting | N=375 --> 3
- ||| rilematovir (JNJ-53718678) / J&J
Enrollment open: PRIMROSE: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov) - Nov 24, 2021
P2b, N=180, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting | N=375 --> 3 Not yet recruiting --> Recruiting
- || rilematovir (JNJ-53718678) / J&J
Enrollment change, Trial completion date, Trial primary completion date: A Study of JNJ-53718678 in Participants With Hepatic Impairment (clinicaltrials.gov) - Nov 8, 2021
P1, N=52, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=32 --> 52 | Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Jun 2021 --> Apr 2022
- || rilematovir (JNJ-53718678) / J&J
Trial primary completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Oct 27, 2021
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
N=32 --> 52 | Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Jun 2021 --> Apr 2022 Trial primary completion date: Dec 2022 --> Mar 2023
- || rilematovir (JNJ-53718678) / J&J
Trial completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Sep 29, 2021
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Mar 2023
- ||||| rilematovir (JNJ-53718678) / J&J
Trial initiation date: DAISY: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Sep 1, 2021
P3, N=737, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Dec 2022 --> Mar 2023 Initiation date: Jan 2021 --> Aug 2021
- || rilematovir (JNJ-53718678) / J&J
Clinical, Journal: Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation. (Pubmed Central) - Jul 31, 2021
PRESORS ClinRO and ObsRO data were collected in a 28-day randomized, double-blind, Phase 1b trial of JNJ-53718678 or placebo in infants and children ≤24 months of age treated for RSV infection in hospitals...PRESORS ClinRO and ObsRO can inform endpoints and enable monitoring the clinical course of RSV in pediatric trials. Improved alignment between ClinRO and ObsRO and revisions ensuring caregivers can assess all signs will be addressed in revised PRESORS.
- ||||| rilematovir (JNJ-53718678) / J&J
New P2b trial: PRIMROSE: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov) - Jul 27, 2021
P2b, N=180, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| rilematovir (JNJ-53718678) / J&J
New P2 trial: Effects of Rilematovir in Adult Outpatients with RSV Infection who are at High Risk for RSV-related Disease Progression (EUDRACT) - Jul 6, 2021
P2, N=180, , Sponsor: Janssen-Cilag International NV
- || rilematovir (JNJ-53718678) / J&J
Trial completion: A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease (clinicaltrials.gov) - Jun 29, 2021
P2a, N=22, Completed, Sponsor: Janssen Research & Development, LLC
Improved alignment between ClinRO and ObsRO and revisions ensuring caregivers can assess all signs will be addressed in revised PRESORS. Active, not recruiting --> Completed
- |||| rilematovir (JNJ-53718678) / J&J
Trial primary completion date: DAISY: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Jun 9, 2021
P3, N=737, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: May 2024 --> May 2025
- ||| rilematovir (JNJ-53718678) / J&J
Enrollment closed, Enrollment change: A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease (clinicaltrials.gov) - May 19, 2021
P2a, N=22, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2024 --> May 2025 Recruiting --> Active, not recruiting | N=1300 --> 22
- || rilematovir (JNJ-53718678) / J&J
Clinical, P1 data, PK/PD data, Journal: Pharmacokinetics, Safety and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized with RSV Infection: A Randomized Phase 1b Study. (Pubmed Central) - Apr 29, 2021
P1b
In RSV-infected infants, JNJ-8678 was well tolerated. Target exposures were reached and antiviral activity was observed.
- | rilematovir (JNJ-53718678) / J&J
Trial completion date, Trial primary completion date: A Study of JNJ-53718678 in Participants With Hepatic Impairment (clinicaltrials.gov) - Apr 22, 2021
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Target exposures were reached and antiviral activity was observed. Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
- | rilematovir (JNJ-53718678) / J&J
Trial completion date: A Study of JNJ-53718678 in Participants With Hepatic Impairment (clinicaltrials.gov) - Mar 17, 2021
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Mar 2021 --> Jun 2021 Trial completion date: Mar 2021 --> Jun 2021
- || rilematovir (JNJ-53718678) / J&J
Trial completion date, Trial primary completion date: A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease (clinicaltrials.gov) - Feb 21, 2021
P2a, N=1300, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2021 --> Jun 2021 Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021
- |||||| rilematovir (JNJ-53718678) / J&J
Enrollment open, Trial completion date: DAISY: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Feb 18, 2021
P3, N=737, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021 Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> May 2025
- || rilematovir (JNJ-53718678) / J&J
Trial completion date: FREESIA: Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Feb 17, 2021
P2, N=375, Recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> May 2025 Trial completion date: Mar 2024 --> Aug 2025
- || rilematovir (JNJ-53718678) / J&J
Trial primary completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Feb 9, 2021
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2024 --> Aug 2025 Trial primary completion date: Nov 2021 --> Dec 2022
- || rilematovir (JNJ-53718678) / J&J
Trial completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Jan 20, 2021
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2021 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022
- | rilematovir (JNJ-53718678) / J&J
Trial primary completion date: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Dec 23, 2020
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Dec 2021 --> Dec 2022 Trial primary completion date: Nov 2020 --> Nov 2021
- || rilematovir (JNJ-53718678) / J&J
New P1 trial: A study in healthy participants to find out how posaconazole interacts with 125mg rilematovir (taken once or twice a day), when they are given together and to find out how long rilematovir stays and acts in the body (pharmacokinetics) when given as 250mg twice a day (EUDRACT) - Dec 10, 2020
P1, N=45, , Sponsor: Janssen-Cilag International NV
- | rilematovir (JNJ-53718678) / J&J
Journal: Discovery of 3 ({5 Chloro-1 [3 (methylsulfonyl)propyl]-1H indol-2 yl}methyl)-1 (2,2,2 trifluoroethyl)-1,3 dihydro-2H imidazo[4,5-c]pyridin-2 one (JNJ-53718678), a potent and orally bioavailable fusion inhibitor of respiratory syncytial virus. (Pubmed Central) - Nov 26, 2020
This publication covers the medicinal chemistry efforts resulting in the identification of JNJ-53718678, an orally bioavailable RSV inhibitor which showed to be efficacious in a phase 2a challenge study in healthy adult subjects and which is currently being evaluated in hospitalized infants and adults. Co-crystal structures of several new derivatives helped rationalizing some of the structure activity relationship (SAR) trends observed.
- | rilematovir (JNJ-53718678) / J&J
Journal: JNJ-5371678, Defining a Role for Fusion Inhibitors in the Treatment of Respiratory Syncytial Virus. (Pubmed Central) - Nov 26, 2020
2020, DOI: 10.1021/acs.jmedchem.0c00226) describe the discovery of JNJ-53718678 which can now claim the leading position in clinical evaluation. For RSV inhibitors, the current status of the clinical development of the compound is discussed.
- || rilematovir (JNJ-53718678) / J&J
Trial completion date: FREESIA: Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Nov 25, 2020
P2, N=375, Recruiting, Sponsor: Janssen Sciences Ireland UC
For RSV inhibitors, the current status of the clinical development of the compound is discussed. Trial completion date: Jul 2024 --> Mar 2024
- |||| rilematovir (JNJ-53718678) / J&J
Enrollment open, Trial completion date: FREESIA: Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Nov 16, 2020
P2, N=375, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial completion date: Jul 2024 --> Mar 2024 Trial completion date: Sep 2022 --> Jul 2024 | Suspended --> Recruiting
- | rilematovir (JNJ-53718678) / J&J
Enrollment open: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (clinicaltrials.gov) - Oct 19, 2020
P2, N=294, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Sep 2022 --> Jul 2024 | Suspended --> Recruiting Suspended --> Recruiting
- | rilematovir (JNJ-53718678) / J&J
Enrollment open: A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease (clinicaltrials.gov) - Oct 19, 2020
P2a, N=1300, Recruiting, Sponsor: Janssen Research & Development, LLC
Suspended --> Recruiting Suspended --> Recruiting
- | rilematovir (JNJ-53718678) / J&J
New P3 trial: DAISY: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (clinicaltrials.gov) - Oct 11, 2020
P3, N=737, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | JNJ-53718678 / J&J
Journal: Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor. (Pubmed Central) - Oct 7, 2020
JNJ-53718678 is primarily eliminated through CYP3A4-mediated metabolism. By integrating duodenal sampling, N-glucuronidation was confirmed as another metabolic pathway despite the low amount of M8 excreted in urine and feces.
- | rilematovir (JNJ-53718678) / J&J
Enrollment open: A Study of JNJ-53718678 in Participants With Hepatic Impairment (clinicaltrials.gov) - Sep 1, 2020
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
By integrating duodenal sampling, N-glucuronidation was confirmed as another metabolic pathway despite the low amount of M8 excreted in urine and feces. Not yet recruiting --> Recruiting